Stockscreener 앱 받기
46.80
0.00%
0.00
시간 외 거래:
46.75
-0.05
-0.11%
Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스
RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC - MarketBeat
(SWTX) Proactive Strategies - news.stocktradersdaily.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc.SWTX - Business Wire
Nuveen Asset Management LLC Has $6.64 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - Benzinga
BNP Paribas Financial Markets Acquires Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Promising Growth Stocks To Research – May 28th - Defense World
ProShare Advisors LLC Acquires 5,503 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Deutsche Bank AG Purchases 19,540 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Merck, SpringWorks receive German antitrust approval for their deal - MLex
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Palisades Investment Partners LLC Purchases 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Bank of America Corp DE Reduces Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Insider Monkey
BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease - Nasdaq
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
142,300 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Zimmer Partners LP - MarketBeat
SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges - Investing.com
Growth Stocks To Consider – May 23rd - Defense World
Growth Stocks To ConsiderMay 23rd - MarketBeat
(SWTX) Investment Analysis - news.stocktradersdaily.com
SpringWorks Therapeutics receives positive CHMP opinion for Mirdametinib for the treatment of adult and paediatric patients with NF1-PN | Health & Wellbeing | Lifestyle - The Phoenix Newspaper UK
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase – Time to Buy? - Defense World
Woodline Partners LP Raises Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Rafferty Asset Management LLC Has $4.44 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Velan Capital Investment Management LP Acquires Shares of 185,520 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Tema Etfs LLC Takes $1.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks’ drug nears EU approval for neurofibromatosis treatment By Investing.com - Investing.com South Africa
SpringWorks Therapeutics (SWTX) Gains EMA Panel Support for Mird - GuruFocus
SpringWorks gets EU endorsement for genetic disorder treatment - Seeking Alpha
SpringWorks’ drug nears EU approval for neurofibromatosis treatment - Investing.com Australia
Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas - marketscreener.com
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - marketscreener.com
SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN - marketscreener.com
SpringWorks: CHMP Adopts Positive Opinion For Mirdametinib - Nasdaq
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mird - GuruFocus
SpringWorks Therapeutics (SWTX) Receives Positive Opinion from E - GuruFocus
SpringWorks Therapeutics (SWTX) Receives Positive Opinion from EMA for Mirdametinib | SWTX Stock News - GuruFocus
SpringWorks Therapeutics Reports Positive CHMP Opinion for Mirdametinib as Potential First Therapy for NF1-PN in EU - Nasdaq
SpringWorks Therapeutics Inc. (SWTX) Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - StreetInsider
SpringWorks Therapeutics Receives Positive CHMP Opinion for - GlobeNewswire
Breakthrough NF1-PN Treatment Scores 52% Response Rate in Children as EU Approval Looms - Stock Titan
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Ensign Peak Advisors Inc - MarketBeat
0.00%
2.33%
자본화:
|
볼륨(24시간):